2021/03-至今, 3044am永利集团官网vip，副研究员

2017/12-2021/03, 3044am永利集团官网vip，校聘研究员

2013/01-2013/06，香港大学，中医药学院，研究助理

2012/07-2014/12，中国科学院昆明植物研究所，研究助理

2013/06-2017/10，香港大学，李嘉诚医学院，博士

2009/09-2012/06，中国科学院昆明植物研究所，硕士

2004/09-2008/06，山西大学，化学化工学院，学士

1）中药活性成分抗心肌缺血再灌注损伤机制研究

2）巨噬细胞介导心肌损伤修复功能研究

3）内源性脂质介质作用靶点及其在疾病的作用研究

1. 国家自然基金面上项目，82074019，“清心除热”中药莲子心介导白三烯代谢LTB4DH/12-oxo-LTB4/SH-PTP1轴抗心肌纤维化分子机制，2021/1-2024/12，55万元，在研，主持

2. 国家自然科学基金青年科学基金项目，81803765，黄芪活性成分芒柄花素靶向GSK-3β蛋白调控巨噬细胞/小胶质细胞极化抗心梗合并抑郁的作用及分子机制，2019/01-2021/12，21万元，在研，主持

3. 广东省自然科学基金面上项目，2019A15150211，Keap1/hnRNPA2B1/miR-210通路介导心肌纤维化的分子机制及中药莲子心干预作用研究，2019/10-2022/10, 10万元，在研，主持

4. 广东省普通高校特色创新项目，2019KTSCX027，10万元，在研，主持

5. 广州市基础研究计划基础与应用基础研究项目，基于ALKBH1蛋白调控线粒体生物功能探讨温补心肾方治疗心肌梗死的作用机制研究，5万元，在研，主持

6.广东省新药筛选重点实验室开放基金项目，GDKLNDS-2018OF001，2018/05-2020/04，已结题，主持

《制药工程原理与设备》、 《制药工程学》、 《制药工程学》课程设计

(1) Yuanyuan Cheng#, Liangkai Cheng#, Xiang Gao, Sixuan Chen, Peng Wu,  Caiyan Wang*, Zhongqiu Liu*. Covalent modification of Keap1 at Cys77 and Cys434 by pubescenoside a suppresses oxidative stress-induced NLRP3 inflammasome activation in myocardial ischemia-reperfusion injury. Theranostics. 2021, 11(2):861-877.

(2) Junxuan Wu#, Sixuan Chen#, Yuntao Liu, Zhongqiu Liu*, Dawei Wang*, Yuanyuan Cheng*. Therapeutic Perspectives of Heat Shock Proteins and Their Protein-Protein Interactions in Myocardial Infarction. Pharmacological Research, 2020, 160:105162

(3) Yuanyuan Cheng*, Jianhui Rong, Pro-resolving lipid mediators as therapeutic leads for  cardiovascular diseases，Expert Opinion on Therapeutic Targets, 2019, 23(5):423-436

(4) Sixuan Chen, Wanyi Guo, Xiaoxiao Qi, Jiuyao Zhou, Zhongqiu Liu, Yuanyuan Cheng*. Natural alkaloids from lotus plumule ameliorate lipopolysaccharide-induced depression-like behavior: integrating network pharmacology and molecular mechanism evaluation. Food & Function, 2019, 10(9):6062-6073

(5) Sixuan Chen, Xuping Li, Junxuan Wu, Jingyan Li, Mingzhu Xiao, Ying Yang, Zhongqiu Liu, Yuanyuan Cheng*. Plumula Nelumbinis: A review of traditional uses, phytochemistry, pharmacology, pharmacokinetics and safety, Journal of Ethnopharmacology. 2021, 10;266:113429.

(6) Ying Yang, Xuping Li, Sixuan Chen, Mingzhu Xiao, Zhongqiu Liu, Jingyan Li*, Yuanyuan Cheng*. Mechanism and therapeutic strategies of depression after myocardial infarction. Psychopharmacology, 2021, doi: 10.1007/s00213-021-05784-0.

(7) Chutian Mai, Meimei Wu, Chunli Wang, Ziren Su*, Yuanyuan Cheng*, Xiaojun Zhang*, Palmatine attenuated dextran sulfate sodium (DSS)-induced colitis via promoting mitophagy-mediated NLRP3 inflammasome inactivation, Molecular Immunology, 2019, 105: 76-85

(8) Yuanyuan Cheng, Yibin Feng, Zhengyuan Xia, Xuechen Li, Jianhui Rong*, omega-Alkynyl arachidonic acid promotes anti-inflammatory macrophage M2 polarization against acute myocardial infarction via regulating the cross-talk between PKM2, HIF-1alpha and iNOS, BBA- Molecular and Cell Biology of Lipids, 2017,1862: 1595-1605

(9) Yuanyuan Cheng, Zhengyuan Xia, Yifan Han, Jianhui Rong*, Plant natural product formononetin protects rat cardiomyocyte H9c2 cells against oxygen glucose deprivation and reoxygenation via inhibiting ROS formation and promoting GSK-3ß phosphorylation, Oxidative medicine and Cellular Longevity, 2016, 2016, 2060874

(10) Yuanyuan Cheng, Chuanbin Yang, Jia Zhao, Hung-Fat Tse, Jianhui Rong*, Proteomic identification of calcium-binding chaperone calreticulin as a potential mediator for the neuroprotective and neuritogenic activities of botanical drug amygdalin, Journal of Nutritional Biochemistry, 2015, 26: 146–154